J. Harrison

Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan

E. Itakura, V. Paly, T. Baker, 2020, Journal of medical economics.

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.

M. Bohensky, D. Liew, A. Gorelik, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

J. Penrod, Shanlian Hu, A. Juárez-García, 2023, PharmacoEconomics - Open.

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.

M. Bohensky, D. Liew, A. Gorelik, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Eastern Cooperative Oncology Group (Ecog) Performance Status (Ps) Is An Independent Predictor Of Hrqol In Unresectable Or Metastatic Melanoma.

J. Harrison, H. Kim, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.